The founders of popular cryptocurrency exchange BitMEX are set to acquire one of the oldest banks in Germany, Bankhaus von der Heydt, which was formed back in 1754. The move will help establish a regulated cryptocurrency products powerhouse in Europe. According to an announcement published by BitMEX a company founded by its CEO Alexander Höptner […]

The post Iceberg Protocol Focused On Utility Development appeared first on Coinpedia - Fintech & Cryptocurreny News Media| Crypto Guide

Saturday – Iceberg Protocol hosted a telegram community-based AMA, in which co-founder and CEO Frank Littiero answered a series of mostly utility-related questions from holders and project supporters. Inquisitive investors made inquiries into future plans and next steps for the hyper-deflationary cryptocurrency project. The community-conscious CEO made it clear that his vision is to complete …

American online personal finance company Social Finance has obtained conditional approval from the Office of the Comptroller of the Currency to establish SoFi Bank, National Association. (Read More)

Spendesk will use the funding to nearly double its workforce.

TOKYO, Jan 19, 2022 - (JCN Newswire) - Honda Motor Co., Ltd. today announced that, in December 2021, the company signed a joint development agreement in the area of Lithium-Metal secondary batteries(1) with SES Holdings Pte. Ltd.("SES"), a U.S. (Boston)-based EV battery research and development company.

Moreover, SES plans to list on the New York Stock Exchange (NYSE) via a special-purpose acquisition company (SPAC) transaction, and through the PIPE (private investment in public equity) offering by the SPAC, Honda plans to acquire approximately 2% of the shares of SES AI Corporation, the company to be listed on NYSE(2)(3).

The battery is a crucial component of battery electric vehicles (EV) and Honda, which is accelerating electrification of its products on a global basis, has been concurrently looking into several options for next-generation batteries, including the all-solid-state batteries Honda is developing independently. This joint development agreement with SES is part of the overall battery strategy of Honda.

From here onward, Honda and SES will pursue joint research for the realization of safe, high-durability and high-capacity next-generation EV batteries.

Comments by Shinji Aoyama, Managing Executive Officer in Charge of Electrification, Honda Motor Co., Ltd., "The battery is an essential component of EVs, and Honda has been concurrently looking into several options toward the realization of high-capacity, safe and low-cost next-generation batteries. Recognizing the advanced technologies of SES, Honda signed a joint development agreement with SES with the aim to establish a good relationship with SES and expeditiously generate substantial achievements through our joint research activities. Honda will continue to establish collaborative relationships with companies which have advanced technologies, as needed, to offer highly-competitive and attractive EVs to our customers."

(1) Batteries with Lithium-Metal anode, which are expected to realize higher energy density than Lithium-ion batteries (which usually use carbon-based materials for the anode).
(2) On October 22, 2021, Honda signed a PIPE subscription agreement with Ivanhoe Capital Acquisition Corp. ("Ivanhoe"), a special-purpose acquisition company (SPAC) listed on the NYSE, pursuant to which Honda is scheduled to acquire shares of Ivanhoe on the day of the merger between SES and a wholly-owned subsidiary of Ivanhoe, with SES the surviving entity ("the merger"), prior to the completion of the merger. Ivanhoe, which will wholly own SES, plans to change its name to SES AI Corporation prior to the completion of the merger. Fulfillment of all prerequisites for the execution of the merger, including approval of SES and Ivanhoe shareholders, is a prerequisite for the stock purchase by Honda.
(3) The shareholding percentage above is based on the assumption that the shareholders of Ivanhoe will not exercise their redemption rights.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHonda Motor Co., Ltd. today announced that, in December 2021, the company signed a joint development agreement in the area of Lithium-Metal secondary batteries(1) with SES Holdings Pte. Ltd.(SES), a U.S. (Boston)-based EV battery research and development company.

TOKYO, Jan 19, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has enrolled the first subject in the phase II/III study (Tau NexGen study). The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).

People who have genetic mutations of DIAD are known to develop Alzheimer's disease (AD) and will likely develop symptoms at around the same age their affected parents did, often in their 50s, 40s or even 30s. The major AD pathologies are amyloid plaque that consists of amyloid beta (Abeta) aggregates; neurofibrillary tangles; and intraneuronal aggregates of tau, all of which are believed to spread throughout the brain.

The purpose of the Tau NexGen study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational therapies in pre-symptomatic or symptomatic participants who have an AD-causing gene mutation. In March 2021, the DIAN-TU selected E2814, which was created from a research collaboration between Eisai and University College London, as the first investigational medicine among anti-tau drugs for the Tau NexGen study. With increasing evidence from clinical studies showing that targeting amyloid can reduce biomarkers of AD, the Tau NexGen clinical trial leaders selected Eisai's investigational anti-Abeta protofibril antibody lecanemab (BAN2401) as the background anti-amyloid therapy, and the study design was amended in November 2021.

Eisai positions neurology as a key therapeutic area, and it will continue to create innovation in the development of novel medicines based on cutting-edge neurology research as it seeks to contribute further to improving the benefits of affected individuals and their families in diseases with high unmet needs, such as dementia including AD.

About Dominantly Inherited Alzheimer Network (DIAN)

The DIAN is an international research effort focused on dominantly inherited Alzheimer's disease. Dominantly Inherited Alzheimer's disease (DIAD) is a rare form of Alzheimer's disease (AD) that causes memory loss and dementia in individuals -- typically while they are in their 30s to 50s. The disease affects less than 1% of the total population of people with AD. The aim of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) is to find solutions to treat or prevent this disease and, potentially, all forms of Alzheimer's. The DIAN-TU is an international public-private partnership dedicated to designing and managing interventional therapeutic trials for individuals with and at risk of DIAD.

About Tau NexGen study

The purpose of the Tau NexGen study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational therapies in people who have an AD-causing gene mutation. In the Tau NexGen study, symptomatic participants will be administered anti-amyloid beta (Abeta) protofibril antibody lecanemab for six months before being randomly assigned to also receive the anti-tau drug or a placebo. Since amyloid plaques accumulate before tau tangles in AD, this study design allows the researchers to assess whether amyloid removal clears the way for the anti-tau drug to function most effectively. Pre-symptomatic participants will be randomly assigned to receive the anti-tau drug or a placebo for a year before beginning lecanemab administration. By staggering the drugs in this way, the researchers will be able to evaluate the effects of the anti-tau drug alone before assessing the effects of the two drugs together. If the primary and secondary endpoints are positive in the analysis two years after the start of study, the study will be extended for another two years to assess whether the drug slows cognitive decline and has further effects on tau pathology.

About E2814

An investigational anti-microtubule binding region (MTBR) tau antibody, E2814 is being developed as a disease modifying agent for tauopathies including sporadic AD. Phase I clinical studies are underway. E2814 was discovered as part of the research collaboration between Eisai and University College London. E2814 is designed to prevent the spreading of tau seeds within the brains of affected individuals.

About Lecanemab (BAN2401)

Lecanemab is an investigational humanized monoclonal antibody for AD that is the result of a strategic research alliance between Eisai and BioArctic. Lecanemab selectively binds to neutralize and eliminate soluble, toxic Abeta aggregates (protofibrils) that are thought to contribute to the neurodegenerative process.

in AD. As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease. With regard to the results from pre-specified analysis at 18 months of treatment, Study 201 demonstrated reduction of brain Abeta accumulation (P<0.0001) and slowing of disease progression measured by ADCOMS* (P<0.05) in early AD subjects. The study did not achieve its primary outcome measure** at 12 months of treatment. The Study 201 open-label extension was initiated after completion of the Core period and a Gap period off treatment (average of 24 months) to evaluate safety and efficacy, and is underway.

Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement concluded with BioArctic in December 2007. In March 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab and the parties amended that agreement in October 2017. Currently, lecanemab is being studied in a pivotal Phase III clinical study in symptomatic early AD (Clarity AD), following the outcome of the Phase II clinical study ( Study 201). In July 2020 the Phase III clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, was initiated. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S., funded by the National Institute on Aging, part of the National Institutes of Health, and Eisai.

In September 2021, a rolling submission to the FDA of a Biologics License Application (BLA) for the treatment of early AD under the accelerated approval pathway was initiated. Lecanemab was granted Breakthrough Therapy designation in June 2021, a U.S. Food and Drug Administration (FDA) program intended to expedite the development and review of medicines for serious or life-threatening conditions.

* Developed by Eisai, ADCOMS (AD Composite Score) combines items from the ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale), CDR (Clinical Dementia Rating) and the MMSE (Mini- Mental State Examination) scales to enable a sensitive detection of changes in clinical functions of early AD symptoms and changes in memory.
** An 80% or higher estimated probability of demonstrating 25% or greater slowing in clinical decline at 12 months treatment measured by ADCOMS from baseline compared to placebo

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120

Eisai Inc (U.S.) Libby Holman 201-753-1945
[email protected]

Investor Contact:
Eisai Co., Ltd.
Investor Relations Department
TEL: +81-(0)70-8688-9685


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comE isai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has enrolled the first subject in the phase II/III study (Tau NexGen study).

Microsoft's acquisition of Activision Blizzard is set to get approval in 2023. Making it the largest in the Games Industry's…

The post Microsoft Acquires Activision Blizzard in $70bn Deal, What does the Future Hold for the Company appeared first on Esports News Network | ESTNN.

The trading platform said the acquisition would help it establish a one-stop-shop for regulated Bitcoin products in Europe.

As the U.S. removes Ethiopia from a critical trade program, it’s clear that the African nation should focus on finding sovereign value.

KARIYA, JAPAN, Jan 17, 2022 - (JCN Newswire) - Leading mobility supplier DENSO, and powertrain supplier Aisan today announced their respective Board of Directors have agreed upon and signed an agreement to transfer DENSO's fuel pump module* business to Aisan. In addition, the Board agreed to allow Aisan to acquire DENSO's equity stake in KYOSAN DENSO MANUFACTURING KENTUCKY, LLC (KDMK), located in Mt. Sterling, KY. The transfer is estimated to be on August 1, 2022.

The two companies previously announced that they reached a basic agreement on May 20, 2019, to begin studying the possibility of strengthening their competitiveness in powertrain and future growth areas. As a result of the study, the companies agreed that DENSO will transfer its entire business of developing, producing, and selling fuel pump modules to Aisan, and Aisan will acquire DENSO's equity stake in KDMK. Additionally, the companies determined that DENSO will not increase its ownership stake in Aisan.

Mutually Beneficial Agreement:

The mutually beneficial agreement will allow DENSO to focus on its Two Great Causes: Green and Peace of Mind, under which it will work to achieve carbon neutrality, zero traffic accidents and safe and seamless society. While, Aisan will work to improve its product capabilities by combining both Aisan and DENSO's technology and knowhow, as well as maximizing resources to improve production efficiency and achieve low-cost manufacturing.

The two companies will continue to collaborate and utilize each other's strengths and contribute to the realization of a sustainable mobility society.

This business transfer is subject to approval from the antitrust authorities in the relevant countries and regions.

* Fuel pump module
An assembly that delivers fuel from the fuel tank to the engine

Overview of business transfer:
Business to be transferred - Fuel pump module
Agreement date - January 17, 2022
Date of the transfer - August 1, 2022 (planned)

About DENSO

DENSO is a $44.6 billion global mobility supplier that develops advanced technology and components for nearly every vehicle make and model on the road today. With manufacturing at its core, DENSO invests in its 200 facilities to produce thermal, powertrain, mobility, electrification, & electronic systems, to create jobs that directly change how the world moves. The company's 168,000+ employees are paving the way to a mobility future that improves lives, eliminates traffic accidents, and preserves the environment. Globally headquartered in Kariya, Japan, DENSO spent 10.0 percent of its global consolidated sales on research and development in the fiscal year ending March 31, 2021. For more information about global DENSO, visit https://www.denso.com/global.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comLeading mobility supplier DENSO, and powertrain supplier Aisan today announced their respective Board of Directors have agreed upon and signed an agreement to transfer DENSO's fuel pump module business to Aisan.

The chief investment officer for Bitwise Asset Management has laid out his argument for why a Bitcoin exchange-traded fund (ETF) will get the greenlight from regulators later this year.  Speaking in an interview with CNBC’s ETF Edge, Bitwise CIO Matt Hougan claimed to be optimistic that the U.S. Securities and Exchange Commission (SEC) will approve […]

TOKYO, Jan 17, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.

At this symposium, the results of a primary analysis of a prospective clinical study evaluating transcatheter arterial chemoembolization (TACE) therapy in combination strategy with lenvatinib (TACTICS-L) in patients with unresectable hepatocellular carcinoma (uHCC) in Japan (Abstract No: 417), as well as research updates on the Phase IV Study (STELLAR) to evaluate safety and tolerability of lenvatinib in patients with advanced/unresectable hepatocellular carcinoma (Abstract No: TPS485) and results from a clinical study to evaluate the efficacy of lenvatinib for conversion surgery in patients with uHCC (investigator-initiated study in Japan, Abstract No: 458), will be presented.

In addition, trial-in-progress (TiP) posters from the clinical program evaluating the combination therapy of lenvatinib plus pembrolizumab (product name: KEYTRUDA), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada), include the Phase III LEAP-014 Study of the combination plus chemotherapy in patients with esophageal carcinoma squamous cell carcinoma (Abstract No: TPS367), Phase III LEAP-015 Study of the combination plus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma (Abstract No: TPS369), Phase III Study LEAP-012 of the combination plus TACE in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment (Abstract No: TPS494), and Phase II Study of the combination plus belzutifan in patients with advanced solid tumors (Abstract No: TPS669).

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Eisai positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

About the Merck & Co., Inc., Kenilworth, N.J., U.S.A. and Eisai Strategic Collaboration

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A.

In addition to ongoing clinical studies evaluating the LENVIMA plus KEYTRUDA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in more than 10 different tumor types across more than 20 clinical trials.

Eisai's Focus on Cancer

Eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from existing in-house discovered compounds) and the driver gene mutation and aberrant splicing (leveraging RNA Splicing Platform) as areas (Ricchi) where real patient needs are still unmet, and where Eisai can aim to become a frontrunner in oncology. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, 'lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.